FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_9C02BE4B6FF2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Production externe
Titre
FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.
Périodique
Movement Disorders
Auteur⸱e⸱s
Wider C., Dachsel J.C., Soto A.I., Heckman M.G., Diehl N.N., Yue M., Lincoln S., Aasly J.O., Haugarvoll K., Trojanowski J.Q., Papapetropoulos S., Mash D., Rajput A., Rajput A.H., Gibson J.M., Lynch T., Dickson D.W., Uitti R.J., Wszolek Z.K., Farrer M.J., Ross O.A.
ISSN
1531-8257[electronic], 0885-3185[linking]
Statut éditorial
Publié
Date de publication
2009
Volume
24
Numéro
3
Pages
455-459
Langue
anglais
Résumé
Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and alpha-synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient-control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and alpha-synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and alpha-synuclein protein levels.
Mots-clé
Adult, Aged, Aged, 80 and over, Female, Fibroblast Growth Factors/genetics, Humans, Male, Middle Aged, Parkinson Disease/genetics, alpha-Synuclein/genetics
DOI
10.1002/mds.22442
Pubmed
19133659
Création de la notice
24/09/2010 19:39
Dernière modification de la notice
20/08/2019 16:02
Données d'usage